Halozyme Therapeutics Inc (HALO)

[friendofthedevil]

While the royalties and raw material sales aren't what some hoped, they aren't bad either. There is growth and the future of the Enhanze "pillar" is solid. HALO has enough cash at current burn to last a few years.

I believe any disappointment comes from realizing how slow enrollment has been into 202. No efficacy numbers for a year puts them six month behind what I had hoped for. Torley had mentioned they had to iron out some of the qualifiers (did she say labs?) to get enrollment going. Hope it is ironed out now since it would take five years to enroll the 420 subjects for ph3 at this rate.